DANBURY, Conn., Nov. 8, 2010 /PRNewswire/ — Biodel Inc.
(Nasdaq:
BIOD) announced today that the following abstracts describing
recent findings from the company’s product development programs
have been accepted for poster presentation at the Tenth Annual
Diabetes Technology Meeting in Bethesda, MD, November 11 and 12,
2010:
“Characterization of Pharmacokinetics and Toleration of Three
Variant Formulations of Linjeta”; presented by Dr. Frank Flacke,
November 12
“A Stabilized Liquid Glucagon Formulation For Bi-hormonal Pump
Use”; presented by Dr. Solomon Steiner, November 12
“A New Formulation of Insulin Glargine with an Extended Release
Profile”; presented by Dr. Roderike Pohl, November 12
“‘Smart’ Basal Insulin Formulation That Releases Insulin in
Response to Changing Blood Glucose Concentrations”; presented by
Nandini Kashyap, November 11
The posters will be available on the company’s website, www.biodel.com.
The Diabetes Technology Meeting focuses on the latest
technological advances for people with diabetes. Its purpose
is to bring together technology developers and users to facilitate
the creation of new and cost-effective tools—including an
artificial pancreas—to help people with diabetes. This
year’s meeting will include sessions on technologies for metabolic
monitoring, biomarkers for early diagnosis of diabetes, the
performance of closed-loop artificial pancreas systems and
alternative delivery routes for insulin.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on
the development and commercialization of innovative treatments for
diabetes. Biodel’s product candidates are developed using
VIAdel™ technology, which reformulates existing FDA-approved
peptide drugs. Linjeta™ is Biodel’s most ad
‘/>”/>
SOURCE
